Overcoming cancer drug-resistance calls for novel strategies targeting abnormal alternative splicing
- 23 July 2024
- journal article
- review article
- Published by Elsevier in Pharmacology & Therapeutics
- Vol. 261, 108697
Abstract
No abstract availableKeywords
This publication has 242 references indexed in Scilit:
- Effects of splicing-regulatory polymorphisms in ABCC2, ABCG2, and ABCB1 on methotrexate exposure in Chinese children with acute lymphoblastic leukemiaCancer Chemotherapy and Pharmacology, 2022
- RNA‐PROTACs: Degraders of RNA‐Binding ProteinsAngewandte Chemie International Edition, 2020
- Elevation of the TP53 isoform Δ133p53β in glioblastomas: an alternative to mutant p53 in promoting tumor developmentThe Journal of Pathology, 2018
- ABCC4 functional SNP in the 3′ splice acceptor site of exon 8 (G912T) is associated with unfavorable clinical outcome in children with acute lymphoblastic leukemiaCancer Chemotherapy and Pharmacology, 2017
- Upregulated miR‐132 in Lgr5+ gastric cancer stem cell‐like cells contributes to cisplatin‐resistance via SIRT1/CREB/ABCG2 signaling pathwayMolecular Carcinogenesis, 2017
- Folylpolyglutamate synthetase splicing alterations in acute lymphoblastic leukemia are provoked by methotrexate and other chemotherapeutics and mediate chemoresistanceInternational Journal of Cancer, 2015
- Antisense-Mediated Exon Inclusion2012
- Trans‐splicingWIREs RNA, 2011
- Upregulation of glycolytic enzymes in proteins secreted from human colon cancer cells with 5‐fluorouracil resistanceElectrophoresis, 2009
- Alternative splicing of Bcl-2-related genes: functional consequences and potential therapeutic applicationsCellular and Molecular Life Sciences, 2004